Treatments

Use of Cannabis have been linked to lower insulin level, 16% for fasting patients and 17% lower on HOMA-IR

Diabetes

The Expanded Endocannabinoid System/Endocannabinoidome as a Potential Target for Treating Diabetes Mellitus. (2019)

Abstract

As with the eCB system, many eCBome members regulate several physiological processes, including energy intake and storage, glucose and lipid metabolism and pancreatic health, which contribute to the development of type 2 diabetes (T2D). Preclinical studies increasingly support the notion that targeting the eCBome may beneficially affect T2D[…]

Author Information

Veilleux A, Di Marzo V, Silvestri C.

École de nutrition, Université Laval, Québec, QC, Canada. Institut sur la nutrition et les aliments fonctionnels, Université Laval, Québec, QC, Canada. Canadian Excellence Research Chair on the Microbiome-Endocannabinoidome Axis in Metabolic Health, Québec, Canada. Institut de cardiologie et de pneumologie de Québec, Université Laval, Québec, QC, Canada. Department de médecine, Université Laval, Québec, QC, Canada. Canadian Excellence Research Chair on the Microbiome-Endocannabinoidome Axis in Metabolic Health, Québec, Canada. cristoforo.silvestri@criucpq.ulaval.ca. Institut de cardiologie et de pneumologie de Québec, Université Laval, Québec, QC, Canada. cristoforo.silvestri@criucpq.ulaval.ca. Department de médecine, Université Laval, Québec, QC, Canada. cristoforo.silvestri@criucpq.ulaval.ca.

Cannabidiol improves metabolic dysfunction in middle-aged diabetic rats submitted to a chronic cerebral hypoperfusion. (2019)

Abstract

Cannabidiol (CBD), a compound obtained from Cannabis sativa, has wide range of therapeutic properties, including mitigation of diabetes and neurodegeneration. Cerebral ischemia and consequent learning disabilities are aggravated in elderly diabetic subjects. However, there are no studies showing the effect of CBD treatment in elderly diabetes patients suffering cerebral ischemia[…]

Author Information

Zorzenon MRT, Santiago AN, Mori MA, Piovan S, Jansen CA, Perina Padilha ME, Ciotta SR, Cezar de Freitas Mathias P, Guimarães FS, Weffort de Oliveira RM, Milani PG, Mareze-Costa CE.

Biochemistry Department, State University of Maringa, Av. Colombo 5790 CEP, 87020-900, Maringa, Parana, Brazil. Electronic address: mariarosazorzenon@hotmail.com. Department of Pharmacology and Therapeutics, State University of Maringa, Av. Colombo 5790 CEP, 87020-900, Maringa, Parana, Brazil. Electronic address: amandan.santiago@gmail.com. Department of Pharmacology and Therapeutics, State University of Maringa, Av. Colombo 5790 CEP, 87020-900, Maringa, Parana, Brazil. Electronic address: marcoaureliomori@gmail.com. Department of Biotechnology, Genetics and Cell Biology, State University of Maringa, Av. Colombo 5790 CEP, 87020-900, Maringa, Parana, Brazil. Electronic address: silvanopionan23@gmail.com. Biochemistry Department, State University of Maringa, Av. Colombo 5790 CEP, 87020-900, Maringa, Parana, Brazil. Electronic address: clerjansen@gmail.com. Biochemistry Department, State University of Maringa, Av. Colombo 5790 CEP, 87020-900, Maringa, Parana, Brazil. Electronic address: eduardapp@hotmail.com. Biochemistry Department, State University of Maringa, Av. Colombo 5790 CEP, 87020-900, Maringa, Parana, Brazil. Electronic address: simone.ciotta@hotmail.com. Department of Biotechnology, Genetics and Cell Biology, State University of Maringa, Av. Colombo 5790 CEP, 87020-900, Maringa, Parana, Brazil. Electronic address: pmathias@uem.br. Centre for Interdisciplinary Research on Applied Neurosciences (NPNA), Department of Pharmacology, Medical School of Ribeirão Preto, University of São Paulo, Av. Bandeirantes 3900 CEP, 14049-900, Ribeirão Preto, São Paulo, Brazil. Electronic address: fsguimar@fmrp.usp.br. Department of Pharmacology and Therapeutics, State University of Maringa, Av. Colombo 5790 CEP, 87020-900, Maringa, Parana, Brazil. Electronic address: rmmwoliveira@uem.br. Biochemistry Department, State University of Maringa, Av. Colombo 5790 CEP, 87020-900, Maringa, Parana, Brazil. Electronic address: pgmfernandes2@uem.br. Department of Physiological Sciences, State University of Maringá, Av. Colombo 5790 CEP, 87020-900, Maringa, Parana, Brazil. Electronic address: cemcosta@uem.br.

Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study. (2019)

Abstract

Cannabidiol (CBD) and Δ(9)-tetrahydrocannabivarin (THCV) are non-psychoactive phytocannabinoids affecting lipid and glucose metabolism in animal models. This study set out to examine the effects of these compounds in patients with type 2 diabetes[…]

Author Information

Jadoon KA, Ratcliffe SH, Barrett DA, Thomas EL, Stott C, Bell JD, O’Sullivan SE, Tan GD.

Division of Medical Sciences & Graduate Entry Medicine, School of Medicine, University of Nottingham, Derby, U.K. St. Pancras Clinical Research, London, U.K. School of Pharmacy, Centre for Analytical Bioscience, University of Nottingham, Nottingham, U.K. Department of Life Sciences, Research Centre for Optimal Health, University of Westminster, London, U.K. GW Pharmaceuticals, Cambridge, U.K. Division of Medical Sciences & Graduate Entry Medicine, School of Medicine, University of Nottingham, Derby, U.K. saoirse.osullivan@nottingham.ac.uk. NIHR Oxford Biomedical Research Centre, Oxford Centre for Diabetes, Endocrinology & Metabolism, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, U.K.

Treatments
_